Business Context and Reporting Period
Company: Wound Management Technologies, Inc. (WMT)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2010
Business Overview: WMT focuses on developing and marketing advanced wound care products, primarily through its subsidiary Wound Care Innovations, LLC (WCI), which holds rights to the CellerateRX collagen product. The company also expanded into secure health data solutions via the acquisition of Secure eHealth and holds a patent for resorbable bone products. The company is classified as a smaller reporting company.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2010 | Nine Months Ended Sep 30, 2010 |
|---|---|---|
| Total Revenue | $111,652 | $292,609 |
| Cost of Revenue | $296,641 | $345,455 |
| Gross Profit (Loss) | $(184,989) | $(52,846) |
| Net Loss | $(1,685,279) | $(3,594,375) |
| Loss Per Share (Basic/Diluted) | $(0.05) | $(0.10) |
| Cash and Cash Equivalents | $37,753 | $37,753 (Ending Balance) |
| Total Assets | $7,042,512 | |
| Total Liabilities | $4,755,089 | |
| Stockholders' Equity | $2,287,423 |
Liquidity: The company reported a working capital deficit, with current liabilities ($4,411,696) significantly exceeding current assets ($751,485). Cash flow from operating activities was negative $(1,246,258) for the nine-month period, while financing activities provided $1,912,036.
Material Changes vs. Prior Period
- Revenue: Increased 8% for the three months ended September 30, 2010, compared to the same period in 2009, attributed to the addition of a sales team.
- Cost of Revenue: Increased 202% year-over-year due to minimum annual royalty payments for the CellerateRX patent, which were not incurred in the prior year's comparable period.
- Expenses: General and Administrative (G&A) expenses rose 163% due to new sales staff wages and significant debt-related costs (approx. $206,000 in origination fees paid in stock).
- Net Loss: Net loss increased 551% for the three-month period, driven by higher operating expenses, royalty payments, and amortization of intangible assets acquired in late 2009.
- Debt Settlement: The company recognized a loss on debt settlement of $1,195,219 for the nine months ended September 30, 2010, primarily from settling debt with stock at values below market price.
Outlook, Risks, and Contingencies
- Going Concern: The filing includes a "Going Concern" qualification. The company has current liabilities in excess of current assets and relies on the issuance of stock and notes payable to fund operations. There is substantial doubt about the company's ability to continue as a going concern without additional funding.
- IRS Liability: The company is delinquent on 2005-2006 payroll taxes. As of September 30, 2010, unpaid taxes totaled approximately $172,484, with penalties and interest of $199,058. A tax lien was filed in December 2009.
- Future Operations: Management anticipates FDA clearance for resorbable bone products in Q1 2011. A significant sales order of over $300,000 received on September 30, 2010, is expected to ship in Q4 2010.
- Capital Needs: The company explicitly states it will need to raise additional capital in fiscal year 2010 to fund its business plan. Failure to do so may require curtailing operations.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $37,753 cash balance against the negative operating cash flow of $(1.2M) for the nine-month period.
- Debt Structure: Review the terms of related-party notes ($2.1M) and convertible debentures ($570k), noting the high interest rates and stock-based interest payments.
- IRS Status: Confirm the status of the tax lien and the company's plan to settle the ~$371k in total payroll tax liabilities.
- Revenue Recognition: Validate the timing of the $316k sales order received on the last day of the quarter and its impact on Q4 revenue.
- Related Party Transactions: Scrutinize the valuation of stock issued for debt settlement and the terms of loans from affiliates of the CEO.